Publications by authors named "Yuko Nagaoki"

Claim this Profile
I
Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma.
Yuko Nagaoki, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino

Therap Adv Gastroenterol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single site study to investigate the current prevalence of anti-hepatitis C virus antibody among substance use disorder patients in Hiroshima-Insufficient testing and diagnosis.
Ariyuki Kagaya, Yuko Nagaoki, Satomi Shimura, Katsuyoshi Kawana, Kazuaki Chayama

Neuropsychopharmacol Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of labor analgesia on mode of delivery and neonatal outcomes in Japan: A retrospective cohort study.
Shu Eguchi, Yuko Nagaoki, Sachiko Ohde, Michio Hirata

PLoS One· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample.
Yuko Nagaoki, Aya Sugiyama, Megumi Mino, Hiroomi Kodama, Kanon Abe

Hepatol Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of Helicobacter pylori infection in the general population evaluated by a resident-register-based epidemiological study.
Masanori Ito, Aya Sugiyama, Megumi Mino, Masaomi Kodama, Yuko Nagaoki

J Gastroenterol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exacerbation of Portal Hypertensive Enteropathy after Endoscopic Injection Sclerotherapy for Esophageal Varices.
Ichiro Otani, Shiro Oka, Hiroshi Aikata, Sumio Iio, Akiyoshi Tsuboi, Yuko Nagaoki

Digestion· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study.
Yuko Nagaoki, Hideyuki Hyogo, Yuwa Ando, Yumi Kosaka, Shinsuke Uchikawa

BMC Gastroenterol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures.
Yuno Nishida, Tomokazu Kawaoka, Michio Imamura, Maiko Namba, Yasutoshi Fujii, Yuko Nagaoki

Intern Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients.
Yuko Nagaoki, Michio Imamura, Yuji Teraoka, Kei Morio, Hatsue Fujino

Hepatol Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study.
Yuji Ogawa, Takashi Kobayashi, Yasushi Honda, Takaomi Kessoku, Wataru Tomeno, Yuko Nagaoki

Hepatol Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
Yuko Nagaoki, Michio Imamura, Yuno Nishida, Kana Daijo, Yuji Teraoka

J Med Virol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Factors of Portal Hypertensive Enteropathy Exacerbation in Patients with Liver Cirrhosis: A Capsule Endoscopy Study.
Sayoko Kunihara, Shiro Oka, Shinji Tanaka, Ichiro Otani, Atsushi Igawa, Yuko Nagaoki

Digestion· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring.
Fumi Honda, Akira Hiramatsu, Hideyuki Hyogo, Hiroshi Aikata, Kana Daijo, Yuko Nagaoki

PLoS One· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.
Masahiro Hatooka, Tomokazu Kawaoka, Hiroshi Aikata, Yuki Inagaki, Kei Morio, Yuko Nagaoki

BMC Cancer· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance of small-bowel villous edema in patients with liver cirrhosis: A capsule endoscopy study.
Ichiro Otani, Shiro Oka, Shinji Tanaka, Akiyoshi Tsuboi, Sayoko Kunihara, Yuko Nagaoki

J Gastroenterol Hepatol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis.
Yuko Nagaoki, Hiroshi Aikata, Kana Daijyo, Yuji Teraoka, Fumi Honda

Hepatol Res· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma.
Yuji Teraoka, Tomoki Kimura, Hiroshi Aikata, Kana Daijo, Mitsutaka Osawa, Yuko Nagaoki

Hepatol Res· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.
Takashi Nakahara, Hideyuki Hyogo, Atsushi Ono, Yuko Nagaoki, Tomokazu Kawaoka

J Gastroenterol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis.
Yuko Nagaoki, Hiroshi Aikata, Kana Daijyo, Yuji Teraoka, Fumi Shinohara

Hepatol Res· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
Kazuhiko Masuda, Atsushi Ono, Hiroshi Aikata, Tomokazu Kawaoka, C Nelson Hayes, Yuko Nagaoki

J Gastroenterol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
Kazuhiko Masuda, Atsushi Ono, Hiroshi Aikata, Tomokazu Kawaoka, C Nelson Hayes, Yuko Nagaoki

J Gastroenterol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury.
Kei Morio, Michio Imamura, Kana Daijo, Yuji Teraoka, Fumi Honda, Yuko Nagaoki

J Gastroenterol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Hiromi Kan, Michio Imamura, Yoshiiku Kawakami, Kana Daijo, Yuji Teraoka, Yuko Nagaoki

J Med Virol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Yuko Nagaoki, Michio Imamura, Hiroshi Aikata, Kana Daijo, Yuji Teraoka

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia.
Kana Daijo, Tomokazu Kawaoka, Takashi Nakahara, Yuko Nagaoki, Masataka Tsuge

Clin J Gastroenterol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis